Global Companion Diagnostics Industry Research 2024:
Dublin, May 20, 2024 (GLOBE NEWSWIRE) -- The
Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dublin, May 20, 2024 (GLOBE NEWSWIRE) -- The
On May 15, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc (NASDAQ:MYGN), executed a significant transaction by selling 227,844 shares of the company.
On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing.
Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price increased by Piper Sandler from $23.00 to $28.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other equities research analysts have also issued reports on MYGN. Leerink Partnrs upgraded shares […]
Marketresearch.biz reports that the The global Personalized Medicine Biomarkers Market was valued at USD 15.5 Billion in 2022. It is expected to reach USD 67.6 Billion by 2032, with a CAGR of 16.3% during the forecast period from 2023 to 2032.Overview of the Personalized Medicine Biomarkers MarketThe Personalized Me...